OXIDATIVE STRESS INDICATORS IN THE DYNAMICS OF TREATMENT WITH RAPID-AND SLOW-ACTING SYMPTOM-MODIFYING DRUGS FOR OSTEOARTHROSIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The investigation conducted in 111 patients with osteoarthrosis (OA) has shown that the rate of oxidative stress is more significantly decreased by drugs that affect the direct and selective inhibition of interleukin-1ß elaboration and are involved in the mechanism responsible for blocking the receptors of this cytokine, one of the key factors of the pathogenesis of OA.

Full Text

Restricted Access

About the authors

L. Shirokova

Yaroslavl State Medical Academy

Email: Larshir@gmail.com

S. Noskov

Yaroslavl State Medical Academy

K. Shirokova

Yaroslavl State Medical Academy

S. Dybin

Yaroslavl Regional Clinical Hospital Three

Yaroslavl

Ya. Politov

Yaroslavl State Medical Academy

M. Mokrousova

Yaroslavl State Medical Academy; Yaroslavl Regional Clinical Hospital Three

Yaroslavl

E. Andreichenko

Yaroslavl State Medical Academy

References

  1. Алексеева Л.И., Шарапова Е.П. Результаты многоцентрового годичного исследования препарата Дьюралан // Эффективн. фармакотер. - 2011; 1: 50-7.
  2. Бадалов Н.Г. Комплексное лечение больных остеоартрозом // Consilium Мedicum. - 2008; 10 (7): 10-4.
  3. Дубиков А.И., Череповский A.B., Белоголовых Л.А. и др. Роль оксида азота в патологии опорно-двигательного аппарата // Научно-практ. ревматол. - 2004; 3: 78-83.
  4. Насонов Е.Л., Насонова В.А. Рациональная фармакотерапия ревматических заболеваний / М.: Литтерра, 2007; 448 с.
  5. Носков С.М., Дыбин С.Д., Широкова Л.Ю. и др. Способ локальной терапии производными аутологичной крови пациентов ревматологического профиля. Разрешение на применение новой медицинской технологии. Заявитель МКУЗ «МСЧ ЯЗДА», рег. уд. ФС № 2010/327.
  6. Слесарев В.И. Химия: Основы химии живого / СПб.: Химиздат, 2005; 784 с.
  7. Стальная И.Д. Современные методы в биохимии / М.: Медицина, 1977; 63-4.
  8. Calich A., Domiciano D., Fuller R. Osteoarthritis: can anti-cytokine therapy play a role in treatment? // J. Clin. Rheumatol. - 2010; 29 (5): 451-5.
  9. Davies C., Guilak F., Weinberg J. et al. Reactive nitrogen and oxygen species in interleukin-1-mediated DNA damage associated with osteoarthritis // Osteoarthr. Cartil. - 2008; 16 (5): 624-30.
  10. de Isla N., Stoltz J. In vitro inhibition of IL-1 beta catabolic effects on cartilage: a mechanism involved on diacerein anti-OA properties // J. Biorheol. -2008; 45 (3): 433-8.
  11. Frisbie D., Kawcak C., Werpy N. et al. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis // Am. J. Vet. Res. - 2007; 68 (3): 290-6.
  12. Lim W., Toothman J., Miller J. et al. IL-1 beta inhibits TGF-beta in the temporomandibular joint // J. Dent. Res. - 2009; 88 (6): 557-62.
  13. Wehling P., Moser C., Frisbie D. et al. Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy // J. BioDrugs. - 2007; 21 (5): 323-32.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies